ACCESS
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 200 patients (estimated)
- Tags
- Allogeneic Stem Cell Transplant, Myeloablative Conditioning (MAC), Nonmyeloablative Conditioning (NMA), Post-Allogeneic Stem Cell Transplant, Pre-Transplant, Reduced Intensity Conditioning (RIC)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1268
- NCT Identifier
- NCT04904588
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.